Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T13:21:43.973Z.
Calculation as of: 2026-10-06T13:21:43.973Z.
Quote observation: 2026-10-05T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c8d7801cb5d69976804150322740a3f9972799eb944d256c77d6faa31d53dc8f
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
EUDA Health Holdings Limited
Market Cap
$32.31M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$31.36M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$35.89M
EV/EBIT Ratio
N/A
TTM Avg
50.30x
3Y Avg
467.13x
5Y Avg
265.91x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| EUDA Health Holdings Limited (EUDA) | $32.31M | N/A | N/A | N/A | N/A |
| BeyondSpring Inc. (BYSI)vs › | $32.32M | N/A | N/A | N/A | N/A |
| Baird Medical Investment Holdings Limited (BDMD)vs › | $31.36M | N/A | N/A | N/A | N/A |
| Aligos Therapeutics, Inc. (ALGS)vs › | $33.42M | N/A | N/A | N/A | N/A |
| Grace Therapeutics, Inc. (GRCE)vs › | $33.52M | N/A | N/A | N/A | N/A |
| Context Therapeutics Inc. (CNTX)vs › | $30.92M | N/A | N/A | N/A | N/A |
| CervoMed Inc. (CRVO)vs › | $30.65M | N/A | 0.37x | 0.82x | 0.82x |
| Accuray Incorporated (ARAY)vs › | $35.89M | N/A | 50.30x | 467.13x | 265.91x |
| DocGo Inc. (DCGO)vs › | $36.05M | N/A | 8.66x | 44.05x | 43.98x |
| aTyr Pharma, Inc. (ATYR)vs › | $28.43M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
